[Efficacy and Safety of DCAG Regimen in Patients with Relapsed/Refractory Acute Myeloid Leukemia].

Q4 Medicine

中国实验血液学杂志 Pub Date : 2025-02-01 DOI:10.19746/j.cnki.issn.1009-2137.2025.01.002

Hui-Sheng Zhou, Yu-Qing Li, Yu-Xin Wang, Ya-Lei Hu, Kai-Li Min, Chun-Ji Gao, Dai-Hong Liu, Xiao-Ning Gao

{"title":"[Efficacy and Safety of DCAG Regimen in Patients with Relapsed/Refractory Acute Myeloid Leukemia].","authors":"Hui-Sheng Zhou, Yu-Qing Li, Yu-Xin Wang, Ya-Lei Hu, Kai-Li Min, Chun-Ji Gao, Dai-Hong Liu, Xiao-Ning Gao","doi":"10.19746/j.cnki.issn.1009-2137.2025.01.002","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy and safety of DCAG (decitabine, cytarabine, anthracyclines, and granulocyte colony-stimulating factor) regimen in the treatment of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).Methods: The clinical data of 64 R/R AML patients received treatment at Chinese PLA General Hospital from January 1st, 2012 to December 31st, 2022 were retrospectively analyzed. Primary endpoints included efficacy measured by overall response rate (ORR) and safety. Secondary endpoints included overall survival (OS), event-free survival (EFS) and duration of response (DOR). The patients were followed from enrollment until death, or the end of last follow-up (June 1st, 2023), whichever occurred first.Results: Sixty-four patients who failed prior therapy were enrolled and completed 1 cycle, and 26 and 5 patients completed 2 and 3 cycles, respectively. Objective response rate was 67.2% ［39: complete remission (CR)/CR with incomplete hematologic recovery (CRi), 4: partial remission (PR)］. With a median follow-up of 62.0 months (1.0-120.9), the median overall survival (OS) was 23.3 and event-free survival was 10.6 months. The median OS was 51.7 months (3.4-100.0) in responders (CR/CRi/PR) while it was 8.4 months (6.1-10.7) in nonresponders ( P <0.001). Grade 3-4 hematologic toxicities were observed in all patients. Four patients died from rapid disease progression within 8 weeks after chemotherapy.Conclusion: The DCAG regimen represents a feasible and effective treatment for R/R AML.","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 1","pages":"9-19"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.01.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy and safety of DCAG (decitabine, cytarabine, anthracyclines, and granulocyte colony-stimulating factor) regimen in the treatment of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).

Methods: The clinical data of 64 R/R AML patients received treatment at Chinese PLA General Hospital from January 1st, 2012 to December 31st, 2022 were retrospectively analyzed. Primary endpoints included efficacy measured by overall response rate (ORR) and safety. Secondary endpoints included overall survival (OS), event-free survival (EFS) and duration of response (DOR). The patients were followed from enrollment until death, or the end of last follow-up (June 1st, 2023), whichever occurred first.

Results: Sixty-four patients who failed prior therapy were enrolled and completed 1 cycle, and 26 and 5 patients completed 2 and 3 cycles, respectively. Objective response rate was 67.2% ［39: complete remission (CR)/CR with incomplete hematologic recovery (CRi), 4: partial remission (PR)］. With a median follow-up of 62.0 months (1.0-120.9), the median overall survival (OS) was 23.3 and event-free survival was 10.6 months. The median OS was 51.7 months (3.4-100.0) in responders (CR/CRi/PR) while it was 8.4 months (6.1-10.7) in nonresponders ( P <0.001). Grade 3-4 hematologic toxicities were observed in all patients. Four patients died from rapid disease progression within 8 weeks after chemotherapy.

Conclusion: The DCAG regimen represents a feasible and effective treatment for R/R AML.

查看原文本刊更多论文

[DCAG方案治疗复发/难治性急性髓系白血病的疗效和安全性]。

目的：评价DCAG（地西他滨、阿糖胞苷、蒽环类药物和粒细胞集落刺激因子）方案治疗复发/难治性（R/R）急性髓系白血病（AML）患者的疗效和安全性。方法：回顾性分析2012年1月1日至2022年12月31日中国人民解放军总医院收治的64例急性髓系白血病患者的临床资料。主要终点包括以总有效率（ORR）和安全性衡量的疗效。次要终点包括总生存期（OS）、无事件生存期（EFS）和反应持续时间（DOR）。患者从入组到死亡，或最后一次随访结束（2023年6月1日），以先发生者为准。结果：入组64例既往治疗失败的患者完成1个周期，完成2个周期和3个周期的患者分别为26例和5例。客观有效率为67.2%[39：完全缓解(CR)/CR伴不完全血液学恢复（CRi）， 4：部分缓解（PR）]。中位随访时间为62.0个月（1.0-120.9），中位总生存期（OS）为23.3个月，无事件生存期为10.6个月。应答者（CR/CRi/PR）的中位OS为51.7个月（3.4-100.0），无应答者的中位OS为8.4个月（6.1-10.7）(P)。结论：DCAG方案是治疗R/R AML的一种可行有效的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊